Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Endometrial Cancer : A Prospective, Single-arm, Open-label Clinical Study

NCT06363708 is registered in ClinicalTrials.gov with Zhongnan Hospital as lead sponsor.

NCT NCT06363708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06363708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Endometrial Cancer : A Prospective, Single-arm, Open-label Clinical Study
Lead sponsor
Zhongnan Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
June 1, 2024
Completion date
June 30, 2026
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial neoplasms